Fingerprint
Dive into the research topics where Frankie Yates is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure
Rawstron, A., Maycock, S., Yates, F., Jarvis, R., Hillmen, P. & Boucher, B., 5 Nov 2020, In: Blood. 136Research output: Contribution to journal › Article
-
Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study
Hillmen, P., Rawstron, A. C., Brock, K., Munoz Vicente, S., Yates, F., Bishop, R., Boucher, B., McDonald, D., Fegan, C., McCaig, A., Schuh, A., Pettitt, A., Gribben, J., Patten, P., Devereux, S., Bloor, A., Fox, C., Forconi, F. & Munir, T., 20 Oct 2019, In: Journal of Clinical Oncology . 37, 30, p. 2722-2729 8 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile71 Citations (Scopus)384 Downloads (Pure) -
The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease
Appleby, N., Eyre, T. A., Cabes, M., Jackson, A., Boucher, R., Yates, F., Fox, S., Rawstron, A., Hillmen, P. & Schuh, A., Dec 2019, In: BMC Cancer.Research output: Contribution to journal › Article › peer-review
-
Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study
Rawstron, A. C., Munir, T., Munoz Vicente, S., Brock, K., Yates, F., Bishop, R., Dalal, S., de Tute, R. M., Bloor, A., Sheehy, O. M., Pettitt, A. R., Fox, C., Fegan, C., Devereux, S., MacDonald, D. & Hillmen, P., 1 Dec 2016, (E-pub ahead of print) In: Blood. 128, 22, p. 2049-2049 1 p.Research output: Contribution to journal › Abstract › peer-review
-
The LLR TAP IcICLLe Trial: Detailed assessment of the response to ibrutinib provides insights into the mode of action and pattern of response in treatment naïve and refractory CLL
Rawstron, A. C., Munir, T., Eccleston, K., Dalal, S., de Tute, R. M., Brock, K., Yates, F., Bloor, A., Fox, C., Fegan, C., MacDonald, D. & Hillmen, P., Jul 2015.Research output: Contribution to conference (unpublished) › Abstract › peer-review
Activities
- 1 Conference, workshop or symposium
-
Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
Brock, K. (Contributor), Hillmen, P. (Speaker), Munir, T. (Contributor), Rawstron, A. (Contributor), Munoz Vicente, S. (Contributor), Yates, F. (Contributor) & Bishop, R. (Contributor)
7 Dec 2017Activity: Academic and Industrial events › Conference, workshop or symposium